Figure 6.
SLeA and/or sLeX determine the efficacy of BZM in additional cell-line-based and patient-derived, organoid-based models
(A) s.c. primary tumor growth periods and tumor weights as well as spontaneous lung metastasis numbers at necropsy of indicated human tumor cell line xenografts treated with PBS or BZM. This treatment was carried out as in Figures 2A and 2B. The minor effect on the tumor growth period upon BZM treatment (GC5023) was considered as a covariate in the statistical analysis of lung metastasis numbers (ANCOVA). (B) Number of adhesive events of SKOV3 cells on ECs treated ± IL1α ± BZM ± E-selectin-blocking antibody and on immobilized rhE-selectin. Representative histograms of tumor-cell-surface sLeA/X expression and static E-selectin binding capacity of SKOV3 cells. (C) s.c. primary tumor growth periods and tumor weights as well as spontaneous lung metastasis numbers at necropsy of SKOV3 xenografts treated with PBS or BZM. This treatment was carried out as in Figures 2A and 2B. (D) Anti-sLeA immunostainings of in-vitro-cultivated versus in-vivo-grown SKOV3 cells versus xenograft tumors, respectively. (E) Representative histograms of tumor-cell-surface sLeA/X expression and static E-selectin binding capacity on patient-derived, organoid-based colorectal cancer models as indicated. (F and G) Numbers of adhesive interactions of single-cell suspensions of these models on immobilized rhE-selectin (F) and ECs treated ± IL-1α ± BZM ± E-selectin-blocking antibody (G). Bar charts represent mean ± SD of n = 10 (A and C) or three replicates (B, F, and G); black lines in histograms represent isotype controls or binding of human IgG1-Fc (C); ∗p < 0.05.